<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2017091736244N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2017-11-10</date_registration>
      <primary_sponsor>Cancer Research Center, Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Vitamin D supplementation and breast cancer prevention</public_title>
      <acronym></acronym>
      <scientific_title>Assessment the effect of vitamin D supplementation on plasma vitamin D levels, inflammatory and antioxidant biomarkers and factors associated with cell proliferation, differentiation, damage and appopotosis in breast cancer survivor</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2016-02-02</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>165</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/27153</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.</study_design>
      <phase>2</phase>
      <hc_freetext>Breast Cancer Survivour.</hc_freetext>
      <i_freetext>Supplement therapy with daily dose of 4000 IU cholecalciferol for 12 weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Seyed Hossein Davoudi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 7, Hafezi st. Farahzadi Blv, Shahrake Gharb</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 2236 0662</telephone>
        <email>hdavoodi1345@gmail.com</email>
        <affiliation>1)	Cancer Research Center, Shahid Beheshti University of Medical Sciences 2)	Department of Nutrition</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Elham Kazemian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 7, Hafezi st. Farahzadi Blv, Shahrake Gharb</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 2236 0662</telephone>
        <email>kazemianelham@yahoo.com; kazemianelham@sbmu.ac.ir</email>
        <affiliation>Department of Basic Sciences and Cellular and Molecular Nutrition, Faculty of Nutrition Sciences and</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria:&#13;
Patients with breast cancer including invasive or in situ carcinoma whose cancer was approved through pathological examination; Women aged 25-65 years; BMI between 25 to 35 kg/m2; not using 1000 IU daily or 50000 IU weekly or 300000 intramuscular injection of vitamin D supplement for at least 4 months before the study; not using dietary, herbal or omega-3 supplements during the intervention period; Patients were diagnosed with breast cancer at least 6 months prior the study and treatment protocols including surgery, radiotherapy and chemotherapy were completed.&#13;
Exclusion criteria:&#13;
History of malabsorption syndrome, calcium metabolism disorder, gastrointestinal, renal, inflammatory (sarcoidosis, etc.) and other endocrinological diseases; Treatment for weight reduction; high levels of plasma vitamin D</inclusion_criteria>
      <agemin>25 years</agemin>
      <agemax>65 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Supplement therapy with daily dose of 4000 IU cholecalciferol for 12 weeks</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Plasma vitamin D level. Timepoint: Baseline and post- intervention. Method of measurement: ELISA.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Oxidative stress biomarkers including Malondialdehyde (MDA), Total Antioxidant Capacity (TAC), Superoxide dismutase (SOD). Timepoint: Baseline and post- intervention. Method of measurement: ELISA and colorometic method.</sec_outcome>
      <sec_outcome>Inflammatory biomarkers including high-sensitivity C-reactive protein (hs-CRP), Tumor necrosis factor alpha (TNFα), Interleukin 6 (IL-6), β-Interferon (IFN-β). Timepoint: Baseline and post- intervention. Method of measurement: ELISA.</sec_outcome>
      <sec_outcome>Biomarkers associated with cell proliferation, differentiation, damage and apoptosis including Matrix metallopeptidase 9 (MMP-9), Plasminogen activator inhibitor-1 (PAI-1), 8-hydroxy-2'-deoxyguanosine (8-OHdG), E-cadherin, B-cell lymphoma2 (Bcl-2), Intercellular adhesion molecule 1 (ICAM-1), Vascular cell adhesion molecule 1 (VCAM-1). Timepoint: Baseline and post- intervention. Method of measurement: ELISA.</sec_outcome>
      <sec_outcome>Anthropometric indicators including Weight, Height, Body Mass Index (BMI), Waist Circumferences, Hip Circumferences, Body Composition. Timepoint: Baseline and post- intervention. Method of measurement: Digital scale,stadiometer, measuring tape.</sec_outcome>
      <sec_outcome>Metabolic profiles including low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, total cholesterol (TC), triglyceride (TG), Aspartate Aminotransferase (SGOT), glutamate-pyruvate transaminase (SGPT), Urea, Creatinine. Timepoint: Baseline and post- intervention. Method of measurement: Colorometic method.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name>Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of</sponsor_name>
      <sponsor_name>Faculty of Nutrition Sciences and Food Technology and National Nutrition and Food Technology Researc</sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Cancer Research Center, Shahid Beheshti University of Medical Sciences</source_name>
      <source_name>Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of</source_name>
      <source_name>Faculty of Nutrition Sciences and Food Technology and National Nutrition and Food Technology Researc</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-01-21</approval_date>
        <contact_name>Ethics committee of faculty of Nutrition Sciences and Food Technology and National Nutrition and Foo</contact_name>
        <contact_address>No 7, Hafezi st. Farahzadi Blvd., Sharake Qods Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
